Unit Director: Prof Salim Abdool Karim
The purpose of the MRC HIV-TB Pathogenesis and Treatment Research Unit at CAPRISA is to undertake research to reduce morbidity and mortality from HIV-TB co-infection. This Unit addresses the leading cause of death in HIV infected patients, in a setting where HIV infection is the largest single contributor to South Africa’s mortality burden and is among the highest research priorities in the SAMRC Strategic Plan.
HIV-infected patients are highly susceptible to TB in the general population and it is widely recognized that TB is the most common opportunistic infection and the leading cause of death among HIV patients. Despite it being a curable disease, TB contributes to unacceptably large numbers of deaths worldwide. In terms of its TB burden, South Africa ranks third highest in the world and HIV co-infection in patients with TB is estimated to be as high as 60% in the country.
The research agenda for the MRC HIV-TB Pathogenesis and Treatment Research Unit includes the disciplines of clinical medicine, epidemiology, biostatistics, immunology, microbiology and public health with 5 focus areas that target HIV-TB co-infection. The goals and objectives of the Unit are:
- Improve survival of HIV-TB co-infected patients by optimizing their treatment
- Generate new knowledge on the pathogenesis and biological interaction between HIV and TB
- Enhance the translation of clinical trial evidence into effective integrated HIV-TB services through implementation science and thereby improve survival in HIV-TB co-infected patients
- Impact on policies and practices aimed at reducing the burden of the dual epidemics in South Africa
- Build research capacity in South Africa
Overview of the MRC HIV-TB Pathogenesis and Treatment Research Unit research plan:
Visit the Centre for the AIDS Programme of Research in South Africa (CAPRISA) Website